AbbVie Inc. on Tuesday said the U.S. Food and Drug Administration approved Qulipta for the preventive treatment of episodic migraine in adults.
The company said Qulipta, or atogepant, "demonstrated statistically significant, clinically meaningful rapid and continuous reductions in mean monthly migraine days among adults with episodic migraine compared to placebo."
Michael Severino, vice chairman and president of AbbVie, said "Millions of people living with migraine often lose days of productivity each month because attacks can be debilitating. Qulipta can help by reducing monthly migraine days with a once-daily, oral dose that works quickly and continuously."
AbbVie said it is the only pharmaceutical company offering three treatments across the full spectrum of migraine.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.